Share this article
Share this article
SAN DIEGO, March 12, 2021 /PRNewswire/ Angiocrine Bioscience Inc., a clinical-stage biopharmaceutical company today announced that they have been selected by the European Society for Blood and Marrow Transplantation (EBMT) for an oral presentation of from AB-205-001, a Phase 1b/2 study to prevent progression to severe organ toxicities in lymphoma subjects undergoing curative high-dose consolidation therapy with autologous hematopoietic cell transplantation (HDT-AHCT). Our investigators and Angiocrine are honored to be selected by EBMT to present at its annual meeting this March, commented Paul Finnegan, MD, Angiocrine CEO. We look forward to Dr. Caroline Mulroney s presentation of AB-205 s efficacy and safety results from our Phase 1b/2 study as well as preparing for the upcoming Phase 3 registration study for this indication.
Angiocrine Bioscience Announces Oral Presentation of AB-205 Data during the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.